Epidemiological profile of malignant neoplasms of the prostate in Brazil - Description of half a decade and the influence of the SARS-CoV-2 pandemic
DOI:
https://doi.org/10.33448/rsd-v13i3.45257Keywords:
Epidemiology; Mortality; Prostatic neoplasms; Hospitalization.Abstract
Prostate cancer (PC) is the 2nd most common in men. When compared with other malignancies, regional and ethnic disparities remain a problem. Screening is carried out through prostate specific antigen (PSA) measurement and digital rectal exam, and, if necessary, biopsy. There is controversy regarding the benefit of annual screening. Given the importance of epidemiological studies, this study aimed to quantify reported cases and describe factors related to the mortality rate and number of hospitalizations for PC between the years 2018 and 2023. The data were obtained from the SUS Information Technology Department (DATASUS), ICD10-C61 (malignant neoplasm of the prostate) by place of residence. The population studied are men aged 40 or over. Epidemiology in Brazil is like developed countries, despite regional disparities. More hospitalizations occurred in the Southeast and fewer in the North, along with the highest mortality rate. Inequalities between Regions are due to unequal access by the State. There is a predominance in the mortality rate at 80 years of age or more and a greater number of hospitalizations at 60 to 69 years of age. Mixed race people had a higher number of hospitalizations. The highest mortality rate occurred in 2021 and the highest number of hospitalizations in 2022 and 2023, which may be influenced by the SARS-CoV-2 pandemic. Analyzing the profile of this neoplasm is essential to guide the planning of public policies, requiring measures to provide more equitable access to health facilities.
References
Bell, K. J., Del Mar, C., Wright, G., Dickinson, J., & Glasziou, P. (2015). Prevalence of incidental prostate cancer: A systematic review of autopsy studies. Int J Cancer, 137(7), 1749-1757. 10.1002/ijc.29538
Bergengren, O., Pekala, K. R., Matsoukas, K., Fainberg, J., Mungovan, S. F., Bratt, O., . . . Carlsson, S. V. (2023). 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review. Eur Urol, 84(2), 191-206. 10.1016/j.eururo.2023.04.021
Brasil. Ministério da Saúde. Secretaria de Atenção Primária à Saúde. Nota técnica n9/2023. (2023). Recomendação pelo não rastreamento populacional do câncer de próstata. Disponível em: https://www.gov.br/saude/pt-br/composicao/saps/publicacoes/notas-tecnicas/notatecnican9_rastreio.pdf
Brasil (n.d.). Ministério da Saúde. Sistema Único de Saúde. Disponível em: https://www.gov.br/saude/pt-br/assuntos/saude-de-a-a-z/s/sus.
Burnett, A. L., Nyame, Y. A., & Mitchell, E. (2023). Disparities in prostate cancer. J Natl Med Assoc, 115(2S), S38-S45. 10.1016/j.jnma.2023.02.003
Carthon, B., Sibold, H. C., Blee, S., & R, D. P. (2021). Prostate Cancer: Community Education and Disparities in Diagnosis and Treatment. Oncologist, 26(7), 537-548. 10.1002/onco.13749
de Oliveira, M. M., Malta, D. C., Guauche, H., de Moura, L., & Silva, G. A. (2015). Estimated number of people diagnosed with cancer in Brazil: data from the National Health Survey, 2013. Rev Bras Epidemiol, 18(2), 146-157. 10.1590/1980-5497201500060013
Dovey, Z. S., Nair, S. S., Chakravarty, D., & Tewari, A. K. (2021). Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies. Cancer Rep (Hoboken), 4(5), e1340. 10.1002/cnr2.1340
Esteban, E. P., & Almodovar-Abreu, L. (2020). A New Interpretation of the Standard PSA-Test. Res Rep Urol, 12, 75-84. 10.2147/RRU.S240171
Etzioni, R., Tsodikov, A., Mariotto, A., Szabo, A., Falcon, S., Wegelin, J., & Feuer, E. (2008). Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control, 19(2), 175-181. 10.1007/s10552-007-9083-8
Evangelista, F. d. M., Melanda, F. N., Modesto, V. C., Soares, M. R., Neves, M. A. B. d., Souza, B. d. S. N. d., & Andrade, A. C. d. S. (2022). Incidence, mortality and survival of prostate cancer in two municipalities with a high human development index in Mato Grosso, Brazil. [Incidência, mortalidade e sobrevida do câncer de próstata em dois municípios com alto índice de desenvolvimento humano de Mato Grosso, Brasil]. Revista Brasileira de Epidemiologia, 25. 10.1590/1980-549720220016.supl.1
Faria, L., Pereira, P., Lustosa, A., Aragão, I., Sant'Anna Aragão, F., & Cunha, M. (2020). Perfil epidemiológico do câncer de próstata no brasil: retrato de uma década. Revista UNINGÁ, 57, 76-84. 10.46311/2318-0579.57.4.076-084
Ferrari, G., Farías-Valenzuela, C., Guzmán-Habinger, J., Drenowatz, C., Marques, A., Kovalskys, I., & Fisberg, M. (2022). Relationship between socio-demographic correlates and human development index with physical activity and sedentary time in a cross-sectional multicenter study. BMC Public Health, 22(1), 669. 10.1186/s12889-022-13117-9
Foley, G. R., Blizzard, C. L., Stokes, B., Skala, M., Redwig, F., Dickinson, J. L., & FitzGerald, L. M. (2022). Urban-rural prostate cancer disparities in a
regional state of Australia. Sci Rep, 12(1), 3022. 10.1038/s41598-022-06958-2
Gomella, L. G., Liu, X. S., Trabulsi, E. J., Kelly, W. K., Myers, R., Showalter, T., & Wender, R. (2011). Screening for prostate cancer: the current evidence and guidelines controversy. Can J Urol, 18(5), 5875-5883.
Kelly, R. S., Vander Heiden, M. G., Giovannucci, E., & Mucci, L. A. (2016). Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence. Cancer Epidemiol Biomarkers Prev, 25(6), 887-906. 10.1158/1055-9965.Epi-15-1223
Klaassen, Z., & Wallis, C. J. D. (2021). Assessing patient risk from cancer and COVID-19: Managing patient distress. Urol Oncol, 39(5), 243-246. 10.1016/j.urolonc.2021.01.023
Lakes, J., & Arsov, C. (2019). [PSA screening and molecular markers]. Urologe A, 58(5), 486-493. 10.1007/s00120-019-0900-y
Lee, A. J. X., & Purshouse, K. (2021). COVID-19 and cancer registries: learning from the first peak of the SARS-CoV-2 pandemic. British Journal of Cancer, 124(11), 1777-1784. 10.1038/s41416-021-01324-x
Lima, A. P. d., Lini, E. V., Giacomazzi, R. B., Dellani, M. P., Portella, M. R., & Doring, M. (2018). Prevalence and factors associated with the performance of prostate cancer screening in the elderly: a population-based study. [Prevalência e fatores associados à realização de exames de câncer de próstata em idosos: estudo de base populacional]. Revista Brasileira de Geriatria e Gerontologia, 21(1), 53-59. 10.1590/1981-22562018021.170054
Loeb, S., Bjurlin, M. A., Nicholson, J., Tammela, T. L., Penson, D. F., Carter, H. B., & Etzioni, R. (2014). Overdiagnosis and overtreatment of prostate cancer. Eur Urol, 65(6), 1046-1055. 10.1016/j.eururo.2013.12.062
Matti, B., & Zargar-Shoshtari, K. (2021). Prostate cancer outcomes disparities: Population survival analysis in an ethnically diverse nation. Urol Oncol, 39(6), 367 e319-367 e326. 10.1016/j.urolonc.2021.02.023
Montironi, R., Santoni, M., Mazzucchelli, R., Burattini, L., Berardi, R., Galosi, A. B., & Scarpelli, M. (2016). Prostate cancer: from Gleason scoring to prognostic grade grouping. Expert Rev Anticancer Ther, 16(4), 433-440. 10.1586/14737140.2016.1160780
Moyer, V. A., & Force, U. S. P. S. T. (2012). Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med, 157(2), 120-134. 10.7326/0003-4819-157-2-201207170-00459
Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G. (2020). Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 31(9), 1119-1134. 10.1016/j.annonc.2020.06.011
Pereira, A. S.; Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. (2018). Metodologias da pesquisa cientifica. UFSM.
Ragsdale, J. W., 3rd, Halstater, B., & Martinez-Bianchi, V. (2014). Prostate cancer screening. Prim Care, 41(2), 355-370. 10.1016/j.pop.2014.02.009
Reeve, B. B., Tan, X., Chen, R. C., Usinger, D. S., & Pinheiro, L. C. (2018). Symptom and function profiles of men with localized prostate cancer. Cancer, 124(13), 2832-2840. 10.1002/cncr.31401
Santos, M. d. O., Lima, F. C. d. S. d., Martins, L. F. L., Oliveira, J. F. P., Almeida, L. M. d., & Cancela, M. d. C. (2023). Estimativa de Incidência de Câncer no Brasil, 2023-2025. Revista Brasileira de Cancerologia, 69(1), e-213700. 10.32635/2176-9745.RBC.2023v69n1.3700
Santos, R. O. M. dos., Abreu, M. M. de., Migowski, A., & Engstrom, E. M.. (2022). Decision aid for prostate cancer screening in Brazil. Revista de Saude
Publica, 56, 19. https://doi.org/10.11606/s1518-8787.2022056003467
Sasse, A. D., Wiermann, E. G., Herchenhorn, D., Bastos, D. A., Schutz, F. A., Maluf, F. C., & Nogueira, L. (2017). First Brazilian Consensus of Advanced Prostate Cancer: Recommendations for Clinical Practice. Int Braz J Urol, 43(3), 407-415. 10.1590/S1677-5538.IBJU.2016.0490
Simbana-Rivera, K., Torres-Roman, J. S., Challapa-Mamani, M. R., Guerrero, J., De la Cruz-Ku, G., Ybaseta-Medina, J., & Martinez-Herrera, J. F. (2023). Regional disparities of prostate cancer mortality in Ecuador: an examination of trends and correlates from 2004 to 2019. BMC Public Health, 23(1), 992. 10.1186/s12889-023-15941-z
U.S.Preventive Services Task Force. (2018). Prostate Cancer Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Marianna Silva Dezembro Leonelo; João Pedro Oliveira Rezende; Pedro Henrique e Silva Álvaro ; Luana Marcelino Mattos Araújo ; José Diogo Pereira Cantarelli ; Victor Oliveira Martins Coelho ; Pedro Henrique Martins de Oliveira
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
